{"id":6956,"date":"2022-04-20T18:30:00","date_gmt":"2022-04-20T18:30:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2021\/"},"modified":"2022-04-20T18:30:00","modified_gmt":"2022-04-20T18:30:00","slug":"nanexa-publicerar-arsredovisning-for-2021","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-arsredovisning-for-2021\/","title":{"rendered":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2021"},"content":{"rendered":"
\n

Nanexa AB (publ) meddelar idag att \u00e5rsredovisningen f\u00f6r 2021 har offentliggjorts och finns tillg\u00e4nglig p\u00e5 bolagets hemsida www.nanexa.com\/finansiella-rapporter<\/a>.<\/p>\n

\u201dUnder 2021 startade vi den f\u00f6rsta kliniska studien med en PharmaShell\u00ae-formulerad produkt, NEX-18, ett mycket stort steg f\u00f6r projektet och f\u00f6r Nanexa. Vi p\u00e5b\u00f6rjade \u00e4ven projekt nummer tv\u00e5, NEX-20, som visade mycket lovande pre-kliniska resultat. Under \u00e5ret genererade vi ocks\u00e5 positiva resultat i olika utv\u00e4rderingsf\u00f6rs\u00f6k med partnerbolag. Nanexa erh\u00f6ll godk\u00e4nnande f\u00f6r grundpatentet avseende PharmaShell\u00ae-belagda l\u00e4kemedel b\u00e5de i Kina, maj 2021, och i Sydkorea, juni 2021. Vi genomf\u00f6rde \u00e4ven en st\u00f6rre finansiering under tredje kvartalet som s\u00e4kerst\u00e4ller fortsatt framdrift och utveckling av bolaget.\u201d, s\u00e4ger David Westberg, vd p\u00e5 Nanexa. <\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar parenterala l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Nanexa \u00c5R 2021 inkl RB<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa AB (publ) meddelar idag att \u00e5rsredovisningen f\u00f6r 2021 har offentliggjorts och finns tillg\u00e4nglig p\u00e5 bolagets hemsida www.nanexa.com\/finansiella-rapporter<\/a>.<\/p>\n

\u201dUnder 2021 startade vi den f\u00f6rsta kliniska studien med en PharmaShell\u00ae-formulerad produkt,<\/p>\n

L\u00e4s mer<\/a><\/p>\n","protected":false},"template":"","class_list":["post-6956","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-annual_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-listing_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexa publicerar \u00e5rsredovisning f\u00f6r 2021 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2021\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2021 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB (publ) meddelar idag att \u00e5rsredovisningen f\u00f6r 2021 har offentliggjorts och finns tillg\u00e4nglig p\u00e5 bolagets hemsida www.nanexa.com\/finansiella-rapporter. \u201dUnder 2021 startade vi den f\u00f6rsta kliniska studien med en PharmaShell\u00ae-formulerad produkt,L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2021\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2021\\\/\",\"name\":\"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2021 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2022-04-20T18:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2021\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2021\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2021 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2021\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2021 - Nanexa AB","og_description":"Nanexa AB (publ) meddelar idag att \u00e5rsredovisningen f\u00f6r 2021 har offentliggjorts och finns tillg\u00e4nglig p\u00e5 bolagets hemsida www.nanexa.com\/finansiella-rapporter. \u201dUnder 2021 startade vi den f\u00f6rsta kliniska studien med en PharmaShell\u00ae-formulerad produkt,L\u00e4s mer","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2021\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2021\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2021\/","name":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2021 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2022-04-20T18:30:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2021\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2021\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2021"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}